一项关于在中国人群中使用灭活 COVID-19 疫苗、Ad5-nCoV 疫苗和/或雾化 Ad5-nCoV 疫苗的有效性的回顾性调查。
A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV.
机构信息
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People's Republic of China.
The Fourth Military Medical University, Xi'an, People's Republic of China.
出版信息
Emerg Microbes Infect. 2024 Dec;13(1):2396875. doi: 10.1080/22221751.2024.2396875. Epub 2024 Aug 30.
Abstract
We administered a questionnaire to participants who received different vaccination regimens to evaluate the effectiveness of Ad5-vectored COVID-19 vaccines. The results showed that administration of intramuscular Ad5-nCoV provided 21.32% more protection against SARS-CoV-2 infection than that of the inactivated COVID-19 vaccine in people who had received only one type of COVID-19 vaccine. Furthermore, aerosolized Ad5-nCoV exhibited good protection, whether it was administered as a homologous booster to people vaccinated with the intramuscular Ad5-nCoV or as a heterologous booster to people vaccinated with inactivated COVID-19 vaccines. Our research indicates that Ad5-nCoV is an effective booster. This finding supports the future selection of COVID-19 immunization strategies.
摘要
我们向接受不同疫苗接种方案的参与者发放了问卷，以评估 Ad5 载体 COVID-19 疫苗的有效性。结果表明，在仅接种过一种 COVID-19 疫苗的人群中，肌内注射 Ad5-nCoV 对 SARS-CoV-2 感染的保护效力比灭活 COVID-19 疫苗高 21.32%。此外，雾化 Ad5-nCoV 表现出良好的保护作用，无论是作为同源加强针接种给肌内注射 Ad5-nCoV 疫苗的人群，还是作为异源加强针接种给灭活 COVID-19 疫苗的人群。我们的研究表明，Ad5-nCoV 是一种有效的加强针。这一发现支持未来选择 COVID-19 免疫策略。
相似文献
1
A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV.一项关于在中国人群中使用灭活 COVID-19 疫苗、Ad5-nCoV 疫苗和/或雾化 Ad5-nCoV 疫苗的有效性的回顾性调查。
Emerg Microbes Infect. 2024 Dec;13(1):2396875. doi: 10.1080/22221751.2024.2396875. Epub 2024 Aug 30.
2
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.成年人接种同源和异源加强疫苗后的免疫反应和转录谱。
Front Immunol. 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024.
3
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗（Ad5-nCoV）在成年人中的安全性、耐受性和免疫原性：一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
4
Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.三剂灭活 SARS-CoV-2 疫苗基础免疫后接种 Ad5-nCoV 的安全性和免疫原性：中国成年人的研究。
Nat Commun. 2023 Aug 8;14(1):4757. doi: 10.1038/s41467-023-40489-2.
5
Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study.中国成年人接种腺病毒 5 型载体新冠疫苗或新冠灭活疫苗加强针第四针的疗效和抗体持续时间研究：一项前瞻性队列研究。
Front Immunol. 2023 Sep 6;14:1244373. doi: 10.3389/fimmu.2023.1244373. eCollection 2023.
6
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study.在奥密克戎为主导的全国性疫情期间，腺病毒 5 型载体 COVID-19 疫苗异源加强剂相对于三剂灭活 COVID-19 疫苗对成年人的相对有效性：一项回顾性、个体匹配的队列对照研究。
Emerg Microbes Infect. 2024 Dec;13(1):2332660. doi: 10.1080/22221751.2024.2332660. Epub 2024 Apr 28.
7
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.三剂科兴疫苗后，雾化腺病毒载体5型新冠疫苗、肌肉注射腺病毒载体5型新冠疫苗或灭活新冠疫苗科兴疫苗作为第二剂加强针的安全性和免疫原性：一项多中心、开放标签、4期随机试验。
Lancet Respir Med. 2023 Jul;11(7):613-623. doi: 10.1016/S2213-2600(23)00049-8. Epub 2023 Mar 7.
8
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.在接种两剂灭活 COVID-19 疫苗的成年人中，使用雾化型 Ad5-nCoV 进行异源加强免疫的安全性、免疫原性和保护效果：一项多中心、开放性 3 期临床试验。
Lancet Infect Dis. 2023 Oct;23(10):1143-1152. doi: 10.1016/S1473-3099(23)00350-X. Epub 2023 Jun 20.
9
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.18 岁及以上成年人中口服雾化双价腺病毒 5 型载体 COVID-19 疫苗和 B.1.1.529 变异腺病毒 5 型载体 COVID-19 疫苗异源加强免疫的安全性和免疫原性：一项随机、双盲、平行对照试验。
Emerg Microbes Infect. 2024 Dec;13(1):2281355. doi: 10.1080/22221751.2023.2281355. Epub 2023 Dec 30.
10
Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.吸入型 COVID-19 疫苗的安全性、免疫原性和保护效果：系统评价和荟萃分析。
J Med Virol. 2024 Apr;96(4):e29625. doi: 10.1002/jmv.29625.
引用本文的文献
1
Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.开发一种新型4型腺病毒载体作为一种有前景的呼吸道疫苗载体。
Front Immunol. 2025 Apr 10;16:1572081. doi: 10.3389/fimmu.2025.1572081. eCollection 2025.
本文引用的文献
1
Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.SARS-CoV-2 mRNA 疫苗（奥密克戎 BA.5）LVRNA012 的有效性、安全性和免疫原性：一项随机、双盲、安慰剂对照的 3 期临床试验。
Front Immunol. 2024 Jun 6;15:1407826. doi: 10.3389/fimmu.2024.1407826. eCollection 2024.
2
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.安全性、免疫原性和异源加强用 SARS-CoV-2 mRNA 疫苗（SYS6006）在中国 18 岁及以上人群中的效果：一项随机、开放标签、阳性对照的 3 期临床试验。
Emerg Microbes Infect. 2024 Dec;13(1):2320913. doi: 10.1080/22221751.2024.2320913. Epub 2024 Feb 29.
3
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study.在奥密克戎为主导的全国性疫情期间，腺病毒 5 型载体 COVID-19 疫苗异源加强剂相对于三剂灭活 COVID-19 疫苗对成年人的相对有效性：一项回顾性、个体匹配的队列对照研究。
Emerg Microbes Infect. 2024 Dec;13(1):2332660. doi: 10.1080/22221751.2024.2332660. Epub 2024 Apr 28.
4
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.鼻内喷雾 SARS-CoV-2 疫苗 dNS1-RBD 的安全性和有效性：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Respir Med. 2023 Dec;11(12):1075-1088. doi: 10.1016/S2213-2600(23)00349-1. Epub 2023 Nov 15.
5
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.中国广东奥密克戎 BA.2 感染突破性感染用灭活 COVID-19 疫苗加强接种的效果：一项队列研究。
Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023.
6
An Observational Prospective Cohort Study of Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection of an Aerosolized, Inhaled Adenovirus Type 5-Vectored Coronavirus Disease 2019 Vaccine Given as a Second Booster Dose in Guangzhou City, China.一项在中国广州市进行的关于吸入用腺病毒载体新冠病毒疫苗作为第二剂加强针的有效性的观察性前瞻性队列研究：预防严重急性呼吸综合征冠状病毒 2 感染的效果。
J Infect Dis. 2024 Jan 12;229(1):117-121. doi: 10.1093/infdis/jiad338.
7
Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.在印度的一项混合匹配研究中，对两种和三种剂量的腺病毒载体疫苗 ChAdOx1 nCov-19 和全病毒灭活疫苗 BBV152 的免疫反应进行了特征描述。
Vaccine. 2023 Jul 25;41(33):4808-4822. doi: 10.1016/j.vaccine.2023.06.059. Epub 2023 Jun 23.
8
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.在接种两剂灭活 COVID-19 疫苗的成年人中，使用雾化型 Ad5-nCoV 进行异源加强免疫的安全性、免疫原性和保护效果：一项多中心、开放性 3 期临床试验。
Lancet Infect Dis. 2023 Oct;23(10):1143-1152. doi: 10.1016/S1473-3099(23)00350-X. Epub 2023 Jun 20.
9
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study.异源加强免疫口服雾化或肌肉注射 Ad5-nCoV 疫苗与同源加强免疫灭活疫苗（BBIBP-CorV 或科兴疫苗）在儿童和青少年中的安全性和免疫原性：一项随机、开放标签、平行对照、非劣效、单中心研究。
Lancet Respir Med. 2023 Aug;11(8):698-708. doi: 10.1016/S2213-2600(23)00129-7. Epub 2023 May 17.
10
Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study.中国针对奥密克戎 BA.2 变异株的灭活新冠病毒疫苗基础免疫和加强免疫的真实世界有效性：一项回顾性队列研究。
J Infect Dis. 2023 Aug 11;228(3):261-269. doi: 10.1093/infdis/jiad090.
Zotero 插件